mobile.zenopa.com Homepage Homepage
Employment Role Location
Business Sector Advanced
Phone 01494 818 000
View company profile
Please contact the Account Manager for opportunities with this organisation

Novo Nordisk begins research into long-acting oral GLP-1 analogue

Posted on 13/01/2010 in Pharmaceutical Company Product News

Novo Nordisk has started its UK-based investigations into the effectiveness of NN9924 - a long-acting oral GLP-1 (Glucagon-Like Peptide-1) analogue for which it has made a payment to Emisphere Technologies.

The firm paid a total of $2 million (1.23 million pounds) to the company, as its Eligen Technology was utilised for the establishment of the compound.

GLP-1, which is a natural hormone involved in controlling blood sugar levels, is being investigated for its safety, tolerability and bioavailability in individuals suffering from type 2 diabetes.

It stimulates the release of insulin when blood sugar levels become too high, as GLP-1 secretion is often impaired in those with the condition, the company highlighted.

Peter Kurtzhals, senior vice-president and head of diabetes research at Novo Nordisk, remarked: "We still have a long road with many challenges ahead of us before a GLP-1 pill becomes a reality."

Last week, Novo Nordisk announced its plans to work alongside Combine to conduct research into autoimmune disease therapies.

Other news stories from 13/01/2010

Read more in the Zenopa News Archive

How this news is generated

Becky
Account Manager
for this opportunity

01494 818 026
(Mon to Fri 0830 to 1800 hours)
becky@zenopa.com

Latest News

Novo Nordisk tops endocrinology image poll

Novo Nordisk to initiate trial of diabetes drug Victoza

Novo Nordisk reports solid first quarter performance

Novo Nordisk reports positive diabetes drug trial data

Novo Nordisk commences global haemophilia survey

home | our clients | browse news | browse jobs | links | hotel directory | Valid HTML | copyright © 2010 Zenopa Ltd | terms & conditions of use